Well said witch. I do agree on the majority of your points. I...

Well said witch. I do agree on the majority of your points. I would look to see clarification from the company as to where they are looking to go forward (and in a hurry). I think given the failure to launch for the drug for obesity that all stops should be pulled out to advance the osteoporisis trial.

As I have said in a previous post I was more encouraged and excited about the use of the drug for osteoporosis rather than obesity, so while we no longer have that avenue for revenue we still have a good target for same. As you rightly indicated a lot of the work - tolerability etc has already been done and paid for, so the osterporosis trial should advance swifty. As also noted from previous poster - jevalent - I think they may have collected extremely valuable data with scans during the obesity trial to use in the osteoporosis trial which is scheduled for 2007 - not sure in what quarter at this stage without looking up. As you also mentioned they have other drugs in the pipeline to carry through with.

They need to quickly inform the market of their new directions and strategies so investors can make informed decisions.

I also hold pending information from company